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Additive manufacturing (AM) offers significant potential benefits in the field of drug delivery 
and pharmaceutical/medical device manufacture. Of AM processes, 3D inkjet printing enables 
precise deposition of a formulation, whilst offering the potential for significant scale up or scale 
out as a manufacturing platform. This work hypothesizes that suitable solvent based ink 
formulations can be developed that allow the production of solid dosage forms that meet the 
standards required for pharmaceutical tablets, whilst offering a platform for flexible and 
personalised manufacture. We demonstrate this using piezo-activated inkjetting to 3D print 
ropinirole hydrochloride. The tablets produced consist of a cross-linked poly(ethylene glycol 
diacrylate) (PEGDA) hydrogel matrix containing the drug, photoinitiated in a low oxygen 
environment using an aqueous solution of Irgacure 2959. At a Ropinirole HCl loading 
of 0.41mg, drug release from the tablet is shown to be Fickian. Raman and IR spectroscopy 
indicate a high degree of cross-linking and formation of an amorphous solid dispersion. This 
is the first publication of a UV inkjet 3D printed tablet. Consequently, this work opens the 
possibility for the translation of scalable, high precision and bespoke ink-jet based additive 
manufacturing to the pharmaceutical sector. 
 
Keywords 
drug delivery, tablet, additive manufacturing, inkjet 3D printing, UV photopolymerization 
Chemical compounds studied in this article 
Ropinirole HCl (PubChem CID: 68727); Poly(ethylene glycol) diacrylate (PubChem CID: 
16212859) 
 
1. Introduction 
With the Federal Drug Administration’s (FDA) approval (FDA, 2015) of Spritam (the first 
commercially produced 3D printed medication, Aprecia Pharmaceuticals) there has been a 
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further increase in interest in additive manufacturing (AM) based platforms to produce both 
personalized medicines and novel function (Alomari et al., 2015). Inkjet printing has been 
highlighted as a promising additive method due to its precision, accuracy, low cost, ability to 
deposit multiple materials contemporaneously, and simple scale up/out, with material 
throughput being dependant on the size of the printer and number of jets (Alomari et al., 2015; 
de Gans et al., 2004; Daly et al. 2015). It is a well-established tool for commercial and consumer 
image production, and has been incorporated into 3D printing methods for prototyping (O’Neil, 
2012) and manufacture (FDA, 2015). For example, the manufacture of Spritam uses a binder 
jetting method whereby an aqueous binder solution is jetted onto a powder-bed (O’Neil, 2012; 
Rowe et al., 2000) in order to build high dose, porous 3D tablet structures which can rapidly 
disintegrate (FDA, 2015). Recent reports of inkjet printed medicines have been focused mainly 
on polymer melts and solutions, which are solidified by drying or cooling and require carrier 
substrates. Hence, the potential to rapidly produce free standing solid dosage forms using UV 
curable materials has yet to be explored in inkjet printing. 
Drop on demand (DoD) printing is a non-contact print method which employs either 
piezoelectric or thermal mechanisms to eject a droplet from the printhead nozzle. In either 
method, a series of droplets are precisely deposited onto a substrate in order to produce two-
dimensional images. Three-dimensional (3D) objects can be generated by sequentially printing 
/ depositing successive two-dimensional (2D) images over multiple layers. However, materials 
availability for inkjet printing are limited, and efforts to broaden the materials range for 
biotechnology applications is an active area of AM research (Begines et al., 2016; He et al., 
2016; Hart et al. 2016; Saunders and Derby, 2014; Gudapati et al., 2016).  In addition to inkjet 
3D printing, other 3D printing technologies have shown significant progress (Alhnan et al., 
2016; Goyanes et al., 2015; Khaled et al., 2015a, 2015b; Okwuosa et al., 2016;  Sadia et al., 
2016). Paste based extrusion printing (Khaled et al., 2015a, 2015b) and fused deposition 
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modelling (Goyanes et al., 2015; Okwuosa et al., 2016; Sadia et al., 2016) have demonstrated 
the potential of fabricating immediate and extended release dosage forms, as well as printing 
“polypills” which contain multiple actives (Goyanes et al., 2015; Khaled et al., 2015a, 2015b), 
starting from approved pharmaceutical grade excipients. 
Recent research in inkjet printed pharmaceuticals has focused on solutions (Alomari et al., 
2015; Genina et al., 2013; Scoutaris et al., 2011; Sandler et al., 2011; Raijada et al., 2013; Lee  
et al., 2012; Acosta-Vélez et al. 2017), nanosuspensions (Pardeike et al., 2011), and melts (Içten 
et al., 2015; Zhu et al., 2013), each of which is primarily 2D. Reel to reel type flexographic 
(Raijada et al., 2013; Palo et al., 2015) printing, as well as inkjet printing in combination with 
electrospinning (Palo et al., 2017) have also been utilized. Sandler et al. investigated the release 
profiles and crystallization behaviour of inkjet-printed solutions of paracetamol, theophylline, 
and caffeine on edible films and porous paper (Sandler et al., 2011). Varan et al. has 
investigated the prolonged release behaviour of inkjet printed paxitaxel in a cyclodextrin 
inclusion complex and cidofovir encapsulated in polycaprolactone nanoparticles dispensed 
onto bioadhesive films (Varan et al., 2017). Low melting temperature PEG/naproxen mixtures 
(Içten et al., 2015; Zhu et al., 2013; Hsu et al., 2015) have been reported for melt based inkjet 
applications in which crystalline domains of the drug could be affected by PEG coatings (Hsu 
et al., 2015), or controlled melt cooling (Içten et al., 2015). Lee et al. successfully produced 
paxlitaxel loaded poly(lactic-co-glycolic acid) microparticles with various geometries 
(honeycombs, grids, rings and circles) and observed that the drug release rate was dependant 
on the surface area of the microparticles (Lee  et al., 2012). However, these printing methods 
are limited in that the doses produced are films, often with an edible substrate incorporated into 
the dosage form. Evaporation of solvent, or cooling of the melt is also necessary in order to 
solidify the dose.  A recent development is that of Acosta-Vélez et al. who reported a 
biocompatible and photocurable ropinirole HCl loaded ink which can be piezo printed, but 
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requires a multistep process involving the manufacture of preformed ‘tablets’ into which the 
ink is deposited (Acosta-Vélez et al., 2017).  
UV curing is widely used in the inkjet printing industry (Yeates et al., 2012) to rapidly solidify 
materials on demand. In this process the ink contains cross-linkable functional groups designed 
to be triggered by light, often with a photoinitiator promoting the process (Yeates et al., 2012). 
Similarly, photocross-linkable resins are used in stereolithography (SLA) printing, an AM 
process in which a vat of the resin is precisely cured by a laser in a layer by layer process to 
generate a 3D object. The suitability and mechanical properties of drug loaded UV curable inks 
have recently been evaluated for SLA based systems (Vehse et al., 2014; Wang et al., 2016) 
with major advantages being the capability to build scaffolds and complex (torus) tablet 
geometries with extended release profiles at ambient temperature (Wang et al., 2016). Despite 
the advantages, however, UV curable inkjet printable formulations have not been reported for 
the fabrication of solid dosage forms. Being able to combine 3D inkjet based printing with UV 
curing offers high resolution, rapid curing and the ability to alter geometry and material 
composition in a flexible, tuneable way. Furthermore, scale-up/out and speed-up of the process 
for commercial production has the potential to be achieved via increasing the number of jetting 
nozzles and/or printheads. 
The scarcity of available photopolymerizable materials and high efficiency photoinitiators 
which are either generally regarded as safe (GRAS) or FDA approved makes UV ink 
formulation challenging. PEG is recognized by the FDA as an inactive tablet ingredient 
(Maximilien, 2009). PEG diacrylate is a network forming free radical addition type cross-linker 
that exhibits biocompatibility (Hoffman, 2002). However, residual unreacted monomer and 
macromer (Norman et al., 2017), as well as photoinitiator related decomposition products may 
be of concern in solid dosage forms depending on the concentrations released during 
dissolution (Williams et al., 2005; Xu et al., 2015). Ropinirole HCl (REQUIP ® 
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GlaxoSmithKline Inc.), a dopamine agonist drug used in the treatment of Parkinson’s and 
restless les syndrome, was chosen as an example drug in this study due to the range of oral 
doses commercially available. It is produced in immediate and extended release dosage forms 
ranging from 0.25 mg to 8.0 mg (GSK, 2015).  
 
2. Materials and Methods:  
2.1. Ink formulation 
Inks were prepared with 0.50 wt % Irgacure 2959 photoinitator (BASF), 30 w t%, 2.00 wt % 
ropinirole HCl (Sequoia Research Products, >98%) and poly(ethylene glycol) diacrylate 
(PEGDA) (M= 700g mol-1, Sigma Aldrich), Irgacure 2959 was stirred into the PEGDA at 
elevated temperature (110°C, 600 rpm) until dissolved. Water and the drug were then stirred 
into the solution (40°C, 600 rpm) until dissolved. The ink was then degassed with nitrogen for 
10 minutes and filtered the solution through a 0.45 mm pore size hydrophilic 13mm diameter 
Millex PTFE filter (Sigma Aldrich) prior to cartridge loading. To block ambient light, which 
can prematurely cure the resin during ink formulation and printing, the ink vessel and cartridge 
were wrapped several times in silver duct tape. To minimize solvent loss during heating and 
degassing stages, the solution was sealed with a rubber septa cap. Base ink (i.e. API free) 
formulations, were prepared for control purposes and formulated with 2 wt % additional 
PEGDA in order to keep the water content constant. All materials were used as received. 
 
2.2. Dynamic viscosity 
In formulating the inks, the viscosity was measured and optimized using a Malvern Kinexus 
Rheometer (Worcester, UK) equipped with a cup and bob type sample geometry at (50°C) at 
fixed shear rate (100 s-1). All measurements were performed in triplicate. 
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2.3. Surface tension 
The surface tension was determined with a Kruss DSA Drop shape analyser at 23°C using the 
Pendant Drop Method. Ten drops were analysed for each ink. 
 
2.4. Printing and processing parameters 
The formulations were printed onto a poly(ethylene terephthalate) (PET) film substrate using 
a Dimatix Materials Printer (DMP-2830 Fujifilm, Lebanon, NH, USA). The printer was 
enclosed in a custom-built glove box and purged with nitrogen gas. O2 levels were kept below 
0.2 % (2000 parts per million, ppm) throughout processing to reduce and control oxygen 
concentrations which can inhibit the curing transformations (i.e. initiation and propagation). 
The Dimatix Materials Cartridge (DMC-11610, Fujifilm Dimatix) contains 16 linearly aligned 
jets, spaced 254 m apart with a ~10 pL drop volume. Curing of the material was carried out 
during printing with a LED UV lamp (365nm, 600 mW cm-2, Printed Electronics Limited, 
Tamworth, UK) bolted directly to the printhead mount and in-line with the print path at print 
cartridge height. He et al. have previously described this method to print polycaprolactone 
dimethacylate based inks (He et al., 2016). This curing unit follows the print and irradiates the 
deposited material during each print pass and at the same print speed. Jetting voltages for each 
nozzle ranged from 20.4 V to 22 V and were individually adjusted to achieve a uniform drop 
speed (1.000 mm per 0.128 ms) at 50°C. The image pattern was a 5.04 mm diameter circle 
bitmap with 847 dpi resolution, corresponding to a 30 mm drop spacing. An array consisting 
of twenty five tablets with a 10 mm (horizontal) start distance from one pattern to the next was 
then generated with the Dimatix Pattern Editor Software. The height of the cartridge was set to 
1.00 mm for the first 100 layers, then repositioned to 1.25 mm for an additional 15 layers to 
provide adequate spacing between the tablet and cartridge as the tablet height increases. To 
post-cure the printed layers, the UV light was scanned over the samples at print speed a total 
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of ten times. To maximize printing speed, all nozzles (16 total) were used, using a high jetting-
frequency (6 kHz) alongside the maximum power level on the UV LED power supply being 
activated. The total printing time was ~ 1.5 hours for each batch of 25 tablets (equating to ~4 
minutes per tablet). To post-cure the printed layers, the UV LED light was scanned over the 
samples at print speed and final cartridge height (1.25 mm) a total of ten times. The post curing 
time was therefore ~7.5 minutes for each batch of 25 tablets (equating to ~18 s per tablet). To 
remove residual water, the prints were dried in a convection oven (Lenton, Eurotherm 3216 
Controller) at 40°C overnight, and then removed from the substrate and stored in a vacuum 
desiccator.  
 
2.5. Tablet swelling and leaching  
Swelling of the tablets was carried out over nine days in 10mL deionized water media at 37°C. 
Media was replaced periodically (five times in total). Samples were carefully blotted with a 
lint free wipe and immediately weighed. Nine base ink tablets and five API tablets were 
analysed. 
 
2.6. Dissolution testing, tablet assay and HPLC methods 
The United States Pharmacopeia (USP) dissolution test II (USP, 2014) was implemented to 
characterize ropinirole HCl release.  A 2.1g L-1 (0.011M) citric acid (99%, Sigma Aldrich) 
dissolution media was prepared with ultrapure 18.2MW-cm water, adjusted to pH=4.0 +/-0.1 
with tris (hydroxymethyl) methylamine (99.9%, Sigma Aldrich), and degassed with He (g). 
Dissolution testing was carried out with a USP grade Erweka (Heusenstamm, Germany) DT600 
series rig in five individual vessels, each containing 500mL +/- 0.01 mL of dissolution media 
and one printed dosage. The vessels were equilibrated to 37.0+/- 0.1°C and equipped with 
rotating USP type I baskets, rotated at 50 rpm. Samples of 5.0 mL were then extracted at times: 
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2, 4, 6, 8, 10, 12, 15, 20, 30, 45, 60, 120, 180, 240 minutes and filtered through 0.45 um pore 
size Millex hydrophilic PTFE membrane filters.  To maintain constant vessel volume, 5.0 mL 
of dissolution media was added to each vessel after each extraction. The procedure was 
repeated for the five additional tablets. A standard calibration curve of ropinirole HCl in the 
dissolution medium was prepared to determine the API concentration in each sample and can 
be found in the Supplementary Data section (Fig. S3). 
A Hewlett Packard Agilent (Santa Clara, CA, USA) 1050 series HPLC system equipped with 
an auto sampler, quaternary pump, degasser, and multi-wavelength UV detector, set at 250 nm, 
was used to detect the API. A 4.6mm x 25cm Supelco Discovery C18 reverse phase column 
(Sigma Aldrich) with 5um particle sized L1 type packing was used to separate the components 
of the samples at ambient temperature, using a flow rate of 1.0 ml/min and a 200 L sample 
injection volume. HPLC Mobile phases were prepared according to USP specifications (USP, 
2014) for ropinirole HCl. Briefly, the mobile phase consisted of an ammonium acetate (98% 
Sigma Aldrich) buffer solution, acetonitrile (Fisher Chemical), and methanol (Fisher 
Chemical), in the volume ratio of 40:7:3 respectively. The buffer solution consisted of 3.85 g 
L-1 ammonium acetate in water, adjusted to pH=2.50 +/- 0.01 with phosphoric acid. All 
solvents used were HPLC gradient grade.  
To assay the API loaded tablets, a 4 ppm ropinirole HCl standard solution standard was 
prepared in ammonium acetate buffer from a 100ppm stock solution. Each tablet was dissolved 
in 100 mL of ammonium acetate buffer solution and stirred for ~2.5 days at room temperature. 
The samples were filtered with 0.45 um pore size PTFE filters (Millex) and were analysed at 
30°C according to the USP method for ropinirole HCl. Testing was carried out in duplicate. 
To analyse the base ink tablets, five base ink tablets were pulverized with a mortar and pestle, 
35 mg of material was added to a 10mL volumetric flask and diluted to volume with ammonium 
acetate buffer. The sample was sonicated for 30 min and dissolved overnight with stirring at 
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room temperature. The samples were filtered with 0.45 um pore size PTFE membrane filters 
and analysed with the HPLC using an injection volume of 20 L. It should be noted that this 
procedure was also performed on five pulverized drug tablets. Results for the drug containing 
tablets indicated incomplete drug release (< 50%). However dissolution may be incomplete. 
 
2.7. FTIR 
 A Frontier FT IR-ATR (Perkin Elmer, Waltham, MA, USA) was used to analyse the samples. 
Samples were scanned from 4000 cm-1 to 600 cm-1 every in steps of 0.5 cm-1. Three scans were 
run for each spectrum with a resolution of 2 cm-1.  
 
2.8. Confocal Raman 
The collection of confocal Raman single point spectra was carried out with a JobinYvon/Horiba 
Raman Spectrometer equipped with a 784 nm infrared laser, 600 nm-1 grating, and 50x 
objective microscope. Slit width was 300 m and collection time was 10s. Scans were made in 
duplicate.  Mapping of 50 m x50 m area was carried out overnight for a total area of 400 
points using a step size of 2.5 m.   
 
3. Results and Discussion 
3.1. Ink characterization 
The formulation and drop requirements for DoD inkjet printing have been extensively studied 
(Daly et al., 2015; Yeates et al., 2012; Martin and Hutchings, 2012; Derby, 2010; Soltman and 
Subramanian, 2008). Optimising the physical properties of the ink, such as the viscosity and 
surface tension, is important for producing drops that can be ejected from the printer. Fujifilm, 
for example, recommends an operating viscosity range of 2 to 30 centipoise (cP), and a surface 
tension of 30 mN m-1 for their Dimatix Printers (Fujifilm, 2008).  The base ink and API 
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containing ink viscosities were 13.58 +/- 0.02 cP and 14.01 +/- 0.03 cP, respectively. The 
surface tension of the base ink and API ink were 40.60 +/- 0.14 mN m-1 and 39.07 +/- 0.30 mN 
m-1, respectively. 
 
3.2. Physical characterization of the printed dosage forms 
Images of the printed tablets can be found in Fig. 1a and Fig. 1d. The tablets were opaque and 
light yellow, in contrast to their light yellow translucent ink solution appearance. Base ink (drug 
free) tablets and ink solutions were translucent and colourless (Fig. S4). Estimated drug loading 
was 0.41 mg calculated based on the solvent free ink composition components and the average 
tablet mass. The average diameters and mass of the dry tablets are also given (Table 1), which 
are well within USP tablet specifications (≤5% weight deviation) (USP, 2000). Optical 
microscopy images in Fig. 1b and Fig. S1 indicate some small “banding” defects along the 
direction of printing, likely caused by rapid solidification of the ink after deposition (Castrejon-
Pita et al., 2013). This can be adjusted by decreasing the UV intensity or print speed, for 
example. Small patches also appear on the print surface. Cross polarized optical microscopy 
(Fig.1c, Fig. S1) indicated that the material in the tablet is amorphous.  
 
3.3 Characterization of API content and tablet swelling 
Swelling and leaching of both the base ink and active pharmaceutical ingredient (API) loaded 
tablets was carried out in deionized water and is summarized in Table 2.  All tablets remained 
intact throughout the test. The percentage of extractable material in the base ink tablets was 
2.7%, indicating low sol content in the gel. The degree of swelling was 44%; while swelling in 
the API loaded tablets was slightly higher (48%). The assayed printed tablets contained 0.39 
+/- 0.01 mg of API material. The percentage recovery, was 97% +/- 0.4% indicating either a 
small amount of degradation of the API or incomplete drug release from the tablets. Degradation 
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of Ropinirole HCl has been reported to occur under oxidative, UV, thermal, high humidity (Reddy et 
al., 2014) and hydrolytic (Parmar et al., 2009; Reddy et al., 2014) conditions. Exposure of the drug to 
UV light, free radicals, water, or heat during the printing process could all affect the drug stability in 
the formulation and tablets. Additional HPLC peaks, were also observed in both the printed API 
and base ink formulations (Fig. 2a), likely corresponding to the photoinitiator and its related 
decomposition products (McGilvray, 2010), which can absorb light at the drug detection 
wavelength. Characteristic chromatograms for the tablet samples and standards, as well as for 
the photoinitiator, are presented in Fig. 2a and Fig. S2, respectively.  
 
3.4. Drug Dissolution  
To characterize drug release from the printed dosage forms, ten tablets were randomly selected 
for dissolution testing. The resultant drug dissolution profile is shown in Fig. 2b. The tablets 
released 89% of the API over four hours, with around 60% being released within the first hour, 
a feature likely owing to the high solubility of the API salt in water and the tablet geometry. It 
was observed that the tablets remained intact throughout the test. 
The mechanism of drug release in the hydrogels was best fitted with the Korsmeyer-Peppas 
model (Table S1). The Korsmeyer-Peppas model can be used to determine drug release from 
polymeric matrix systems according to Eq. (1), where the fraction of drug released, 

M
M
t ,  at 
time, t, is represented (Korsmeyer et al., 1983; Riger and Peppas, 1987; Dash et al., 2010) by 
 
nt
Kt
M
M


                      (1) 
 
where the release exponent, n, defines the type of diffusional transport (i.e. Fickian or non-
Fickian mass transfer) (Riger and Peppas, 1987),  K is the kinetic rate constant, 
t
M  is the 
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amount of drug released at time, t, and 

M is the total amount of drug in the dosage form. In 
this model the first 60% of release data is plotted as the natural log cumulative percentage 
released versus natural log time to determine the release coefficient, n, which is given by the 
gradient of this relationship. It has previously been shown by Ritger and Peppas for cylindrical 
shaped tablets that n≤ 0.45 indicates Fickian transport of the drug from the matrix (Riger and 
Peppas, 1987). The release exponent of 0.43 determined for the hydrogels in this study, 
therefore indicates that Fickian diffusion is the primary mechanism of API release. 
 
3.5. FTIR 
Fourier transform infrared spectroscopy-attenuated total reflection (FTIR-ATR, Perkin-Elmer) 
was used to confirm the presence of the API and to assess the degree of cure on the tablet 
surfaces. A spectrum of crystalline ropinirole HCl is shown in Fig. 3a. Ropinirole HCl was 
observed to have characteristic peaks at 3218 cm-1, 3071 cm-1 (a secondary amide N-H-stretch), 
2601 cm-1 (a tertiary amine salt  N-H+ stretch), 1703 cm-1 (amide C=O stretch), as well as 1614 
cm-1, 1597 cm-1, and 775 cm-1. For comparison, the uncured PEGDA macromer spectra has 
been included; it contains characteristic acrylate peaks at 1722 cm-1 (C=O stretch), 1636 cm-
1and 1618 cm-1 (acrylate C=C stretches) and 810cm-1 (acrylate =CH2 twist) (Lin-Vien et al., 
1991). The top and bottom tablet surfaces were found to contain the API peaks at 3071 cm-1, 
2601 cm-1, 1597 cm-1, 1703 cm-1 and 775 cm-1 confirming the presence of the drug. The acrylate 
related peaks at 810 cm-1, and 1636 cm-1 were not present, indicating a high degree of acrylate 
functional group conversion.  
 
3.6. Confocal Raman 
Confocal Raman was then used to characterize the API in the top surface of the print. Single 
point spectra of the pure drug and the printed base ink, are shown in Fig. 3b. In the drug spectra, 
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a high intensity peak was observed in the fingerprint region at 480cm-1 as well as an amide 
(C=O stretch) at 1704cm-1. In the cured based ink spectra, characteristic broad PEG-related 
peaks were observed, as well as a C=O stretch at 1731cm-1. The spectra for the printed API ink 
formulations, which contain both the polymer matrix and photoinitiator is shown in Fig. 3b. 
Inspection of the spectra of the dosage form suggested that it was a combination of cross-linked 
base polymer and API with no evidence of API related peak broadening. The C=C acrylate 
stretching peak at 1636 cm-1 is also not observed in the single point spectra of the base ink or 
API loaded tablets, signalling high levels of cure. Therefore, only very low levels of unreacted 
di-acrylate monomer appear to remain in the material. Mapping of the API in the printed drug 
loaded tablets was carried out using the intensity of the drug related peak at 480 cm-1 (Fig. 3c). 
The drug related peak is detected throughout the entire mapped area, but variability of the 
intensity was noted. There appears to be at the micron scale drug poor regions as well as drug 
rich ‘hot spots’ in the tablet. To investigate this further, a distribution of the API (red) and base 
ink (blue) was determined by a Classical Least Squares Fit (Fig. 3d) to the mapped data using 
the pure API and cured base ink spectra as references. This fit is consistent with the API peak 
intensity mapping. Whilst there is evidence of heterogeneity in drug distribution at the micron 
scale none of these regions show evidence of drug crystallinity, strongly suggesting the 
formation of a solid dispersion. This is also consistent with the nature of the drug release 
observed for the API. 
4. Conclusions 
In summary, UV inkjet printing has been demonstrated as a platform to produce solid oral 
dosage forms for the first time. A novel UV curable, 3D printable ink was developed 
specifically for ropinirole HCl, a low dose water soluble drug. These tablets were characterized 
by Raman mapping, FTIR-ATR and optical microscopy and shown to be amorphous solid 
dispersions with high degrees of photopolymer curing. The drug release kinetics were 
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determined to follow the Korsmeyer-Peppas power law type release model with Fickian 
diffusion. It is anticipated that this approach can be used with a range of API and photoinitiator 
combinations, assuming compatibility and solubility of the components. As a consequence, 
solid dosage forms produced using this method will provide the opportunity for greater 
flexibility in the pharmaceutical industry in comparison to commonly adopted solid dosage 
manufacturing techniques in a variety of scenarios, including small scale clinical trials, 
personalized medicine, as well as functionally graded dosage design.  
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Fig. 1.  
Images of ropinirole HCl printed tablets. a, d) Image of tablets with 115 layers +10 non-jetting 
post curing print passes. b) Reflection (5x) and c) transmission cross polarized (5x) optical 
22 
 
microscopy images of the top surfaces of the API loaded tablets, respectively. Microscope used 
as a Nikon Eclipse LV100ND Polarizing microscope (Nikon U.K. Ltd., Surry, UK). 
 
 
 Fig. 2.  
Quantification of drug release from the printed tablets. a) HPLC chromatogram of the 4ppm 
ropinirole HCl standard (top), API tablet assay, and printed base ink tablet assay (bottom). b) 
USP II dissolution profile ropinirole HCl release from the tablets in citric acid dissolution 
medium (pH= 4.00). Standard deviation is shown as error bars (n=10). 
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Fig. 3.  
a) FTIR of the formulation components and API tablet surfaces. b) Single point Raman spectra 
of the pure drug (grey), printed base ink (blue), top tablet surface (red) and subtracted spectra 
(black).  Both a drug rich and drug poor spectra are shown for the tablet. Subtracted spectra 
were calculated as the difference between the tablet spectra and the printed base ink. c) Raman 
intensity mapping of the API peak over a 50m x 50 m area. d) Classical least squares fit 
(CLS) of ropinirole HCl (red) and the base ink (blue) of the tablet. Both intensity mapping and 
CLS fit indicate that the dosage form is a solid dispersion with drug rich and poor regions. e) 
A 50x optical microscopy image of the mapped area, as well as the overlaid map coordinates 
(red) and laser location (green). Laser: IR 784 nm, step 2.5 m, 400 pts. 
 
Table 1.  
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Physical Properties of API loaded Tablets. Mass, diameter, and print height of two batches of 
twenty five tablets. Diameter and height were measured with an electronic caliper (Products 
Engineering Corp., USA). 
 
 
Batch no. 
 
Mass  
[mg]a) 
Diameter 
 [mm]b) 
Height  
[mm]c) 
1 14.31 +/- 0.04d) 5.03 +/- 0.01 0.72 +/- 0.02 
 
2 14.17 +/- 0.03 5.02 +/- 0.02 0.72 +/- 0.01 
a)(n= 25 tablets); b)(n= 10 tablets); c)(n= 10 tablets); d) (values reported as mean +/- standard 
deviation)  
 
 
Table 2.  
Degree of swelling and leaching in the API and base ink tablets at 37oC. Tablets were leached 
for nine days in 10mL deionized water. Percent extractable = 100 x (Initial Dry Mass –Final 
Dry Mass)/ Initial Dry Mass. Degree of swelling = 100 x (Swelled Hydrogel Mass –Final Dry 
Mass)/ Final Dry Mass. 
 
API tablets 
Tablet 
no. 
Initial Dry 
Mass  
[mg] 
Final Dry 
Mass 
[mg] 
Swollen Hydrogel 
Mass  
[mg] 
Percent 
extractable  
[%] 
Degree of 
Swelling  
[%] 
2 14.16 13.30 20.01 6.073 50.45 
23 14.08 13.49 19.90 4.190 47.52 
6 14.03 13.45 19.77 4.134 46.99 
12 14.09 13.36 19.76 5.181 47.90 
14 14.12 13.41 19.71 5.028 46.98 
Avg. 14.10 13.40 19.83 4.921 47.97 
S.D. 0.05 0.07 0.12 0.800 1.44 
      
Base ink tablets 
Tablet 
no. 
Initial Dry 
Mass  
[mg] 
Final Dry 
Mass 
[mg] 
Swollen Hydrogel 
Mass  
[mg] 
Percent 
extractable  
[%] 
Degree of 
Swelling  
[%] 
17 14.98 14.45 20.89 3.538 44.57 
10 14.75 14.36 20.62 2.644 43.59 
6 14.8 14.36 20.95 2.973 45.89 
19 14.76 14.39 20.78 2.507 44.41 
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11 14.76 14.41 20.85 2.371 44.69 
15 14.67 14.30 20.74 2.522 45.03 
 13 14.76 14.51 20.79 1.694 43.28 
Avg. 14.79 14.39 20.79 2.696 44.48 
S.D. 0.08 0.07 0.10 0.592 0.90 
 
 
 
